Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976945 | 1.00 | HSD11B1 (0.33) | HSD11B1TSHRACHEP2RX7HTR2A | |
| SCHEMBL11956497 | 0.90 | ACHE (0.31) | HSD11B1TSHRACHEP2RX7HTR2A | |
| SCHEMBL11956498 | 0.90 | ACHE (0.31) | HSD11B1TSHRACHEP2RX7HTR2A | |
| SCHEMBL1895228 | 0.90 | ACHE (0.31) | HSD11B1TSHRACHEP2RX7HTR2A | |
| SCHEMBL1906217 | 0.90 | ACHE (0.31) | HSD11B1TSHRACHEP2RX7HTR2A | |
| SCHEMBL1895230 | 0.90 | ACHE (0.31) | HSD11B1TSHRACHEP2RX7HTR2A | |
| SCHEMBL11956522 | 0.89 | SCN9A (0.31) | HSD11B1ACHEP2RX7 | |
| SCHEMBL1907219 | 0.89 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL1905656 | 0.89 | SCN9A (0.31) | HSD11B1ACHEP2RX7 | |
| SCHEMBL1905654 | 0.89 | SCN9A (0.31) | HSD11B1ACHEP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236789-B2 | 1-adamantyl azetidin-2-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| EP-2322505-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD., (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD3B1, CYP46A1 | HSD11B1 1/4885TSHR 756/4885ACHE 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.